PTK2 and cancer: The results showed that the upregulated mrDEGs were enriched in several cancer-related pathways, such as MET activates PTK2 signaling, PI3K signaling, negative regulation of binding, and positive regulation of Wnt signaling pathway (Fig. 2a).